Valuation: Genelux Corporation

Market Cap 89.62M 80.02M 73.43M 66.79M 125M 8.48B 128M 877M 354M 4.48B 336M 329M 14.15B P/E 2026 *
-2.44x
P/E 2027 * -2.55x
Enterprise Value 89.62M 80.02M 73.43M 66.79M 125M 8.48B 128M 877M 354M 4.48B 336M 329M 14.15B EV / Sales 2026 *
-
EV / Sales 2027 * 11.4x
Free-Float
86.3%
Yield 2026 *
-
Yield 2027 * -
1 day-3.85%
1 week+4.71%
Current month-3.85%
1 month-21.88%
3 months-31.97%
6 months-27.01%
Current year-54.13%
1 week 1.95
Extreme 1.9521
2.27
1 month 1.86
Extreme 1.86
2.66
Current year 1.86
Extreme 1.86
4.99
1 year 1.86
Extreme 1.86
8.54
3 years 1.6
Extreme 1.6
17.48
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 28/05/2014
Director of Finance/CFO 42 30/01/2025
Chief Tech/Sci/R&D Officer 52 02/01/2026
Director TitleAgeSince
Director/Board Member 68 01/09/2002
Chairman 73 01/01/2014
Chairman 67 01/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
31/8/26 Sell

Chief Technology Officer

-9,683 0.0214%
31/8/26 Sell

Chief Executive Officer

-34,463 0.0762%
31/8/26 Sell

Chief Technology Officer

-10,257 0.0227%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%+4.71%-75.25%-87.86% 89.62M
-2.37%-5.03%+39.49%+62.39% 62.23B
-0.28%-0.15%+10.12%+67.87% 54.92B
-0.28%+1.51%+19.70%+96.11% 55.26B
-3.33%-5.54%+19.39%+35.69% 42.59B
-2.45%-2.59%+16.36%+98.45% 41.08B
-1.64%+2.32%+219.80%+789.69% 40.33B
0.00%+23.52%+98.55%+83.27% 33.12B
+0.21%+1.05%+14.81%+46.96% 32.61B
-2.90%+17.12%-42.35%+337.07% 23.98B
Average -1.72%+4.32%+32.06%+152.96% 38.62B
Weighted average by Cap. -1.46%+2.74%+44.51%+162.34%

Financials

2026 *2027 *
Net sales - 7.85M 7.01M 6.43M 5.85M 10.97M 743M 11.19M 76.8M 30.96M 392M 29.46M 28.83M 1.24B
Net income -36.96M -33M -30.28M -27.54M -51.64M -3.5B -52.67M -362M -146M -1.85B -139M -136M -5.83B -40.91M -36.52M -33.52M -30.49M -57.16M -3.87B -58.3M -400M -161M -2.04B -154M -150M -6.46B
Net Debt - -
Projected Income Statement - Annual - Genelux Corporation
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
02/11/26 USD 2.000 -3.85% 526,296
30/10/26 USD 2.080 -0.95% 209,676
29/10/26 USD 2.100 -4.98% 120,302
28/10/26 USD 2.210 +7.80% 523,909
27/10/26 USD 2.050 +7.33% 1,452,184
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Genelux Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.000USD
Average target price
18.83USD
Spread / Average Target
+841.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genelux Corporation
  1. Stock Market
  2. Stocks
  3. GNLX Stock